Primary hyperparathyroidism
Conditions
Brief summary
Effects of ZOL vs. placebo at time of parathyroidectomy on aBMD at lumbar spine, one year after PTX.
Detailed description
Effects on aBMD at distal forearm, femoral neck, and total hip, Effects on microarchitecture measured by high-resolution peripheral computed tomography (HRpQCT), Effects on biochemical bone turnover markers (BTM)., Effects on vBMD at the hip and lumbar spine., Effects on CACS., Effects on PWV., Effects on renal calcifications and urinary analytes.
Interventions
DRUGZoledronic Acid Oresund Pharma 4 mg/100 ml infusionsvätska
DRUGlösning
DRUGNatriumklorid "Baxter" Clear-Flex 9 mg/ml
DRUGinfusionsvæske
DRUGopløsning
Sponsors
Region Midtjylland
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects of ZOL vs. placebo at time of parathyroidectomy on aBMD at lumbar spine, one year after PTX. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects on aBMD at distal forearm, femoral neck, and total hip, Effects on microarchitecture measured by high-resolution peripheral computed tomography (HRpQCT), Effects on biochemical bone turnover markers (BTM)., Effects on vBMD at the hip and lumbar spine., Effects on CACS., Effects on PWV., Effects on renal calcifications and urinary analytes. | — |
Countries
Denmark
Outcome results
None listed